

RESEARCH

Open Access



TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations

Hideyuki Arita^{1,2*}, Yuko Matsushita^{1,3}, Ryunosuke Machida⁴, Kai Yamasaki^{1,5}, Nobuhiro Hata⁶, Makoto Ohno³, Shigeru Yamaguchi⁷, Takashi Sasayama⁸, Shota Tanaka⁹, Fumi Higuchi¹⁰, Toshihiko Iuchi¹¹, Kuniaki Saito¹², Masayuki Kanamori¹³, Ken-ichiro Matsuda¹⁴, Yohei Miyake^{15,16}, Kaoru Tamura¹⁷, Sho Tamai¹⁸, Taishi Nakamura¹⁶, Takehiro Uda¹⁹, Yoshiko Okita^{20,21}, Junya Fukai²², Daisuke Sakamoto²³, Yasuhiko Hattori²⁴, Eriel Sandika Pareira²⁵, Ryusuke Hatae⁶, Yukitomo Ishi⁷, Yasuji Miyakita³, Kazuhiro Tanaka⁸, Shunsaku Takayanagi⁹, Ryohei Otani^{10,26}, Tsukasa Sakaida¹¹, Keiichi Kobayashi¹², Ryuta Saito¹³, Kazuhiko Kurozumi²⁴, Tomoko Shofuda²⁷, Masahiro Nonaka^{20,28}, Hiroyoshi Suzuki²⁹, Makoto Shibuya³⁰, Takashi Komori³¹, Hikaru Sasaki²⁵, Masahiro Mizoguchi⁶, Haruhiko Kishima², Mitsutoshi Nakada¹⁸, Yukihiko Sonoda¹⁴, Teiji Tominaga¹³, Motoo Nagane¹², Ryo Nishikawa¹⁵, Yonehiro Kanemura^{20,27}, Aya Kuchiba⁴, Yoshitaka Narita³ and Koichi Ichimura^{1*}

Abstract

TERT promoter mutations are commonly associated with 1p/19q codeletion in IDH-mutated gliomas. However, whether these mutations have an impact on patient survival independent of 1p/19q codeletion is unknown. In this study, we investigated the impact of *TERT* promoter mutations on survival in IDH-mutated glioma cases. Detailed clinical information and molecular status data were collected for a cohort of 560 adult patients with IDH-mutated gliomas. Among these patients, 279 had both *TERT* promoter mutation and 1p/19q codeletion, while 30 had either *TERT* promoter mutation ($n = 24$) or 1p/19q codeletion ($n = 6$) alone. A univariable Cox proportional hazard analysis for survival using clinical and genetic factors indicated that a Karnofsky performance status score (KPS) of 90 or 100, WHO grade II or III, *TERT* promoter mutation, 1p/19q codeletion, radiation therapy, and extent of resection (90–100%) were associated with favorable prognosis ($p < 0.05$). A multivariable Cox regression model revealed that *TERT* promoter mutation had a significantly favorable prognostic impact (hazard ratio = 0.421, $p = 0.049$), while 1p/19q codeletion did not have a significant impact (hazard ratio = 0.648, $p = 0.349$). Analyses incorporating patient clinical and genetic information were further conducted to identify subgroups showing the favorable prognostic impact of *TERT* promoter mutation. Among the grade II–III glioma patients with a KPS score of 90 or 100, those with *IDH-TERT* co-mutation and intact 1p/19q ($n = 17$) showed significantly longer survival than those with *IDH* mutation, wild-type *TERT*, and intact 1p/19q ($n = 185$) (5-year overall survival, 94% and 77%, respectively; $p = 0.032$). Our results demonstrate that *TERT* promoter mutation predicts favorable prognosis independent of 1p/19q codeletion in IDH-mutated gliomas. Combined with its

*Correspondence: neuro.husky@gmail.com; kichimur@ncc.go.jp

¹ Division of Brain Tumor Translational Research, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
Full list of author information is available at the end of the article



© The Author(s) 2020. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

adverse effect on survival among IDH-wild glioma cases, the bivalent prognostic impact of *TERT* promoter mutation may help further refine the molecular diagnosis and prognostication of diffuse gliomas.

Keywords: *IDH1/2*, *TERT*, 1p/19q codeletion, *CDKN2A*, Glioma

Introduction

Recent advances in molecular genetics over the last decade have facilitated the integration of molecular markers into the diagnosis of brain tumors. The revised 4th edition of the World Health Organization (WHO) classification of Tumours of the Central Nervous System (the CNS WHO 2016) incorporated molecular diagnosis in the diagnostic criteria for the first time in its history [17]. The *IDH1/2* (*IDH*) status plays a crucial role in defining adult diffuse gliomas in the current diagnostic system. *IDH* mutation and 1p/19q codeletion are necessary and sufficient to make the diagnosis of oligodendrogliomas regardless of the histology. The 1p/19q codeletion is the key diagnostic marker to delineate oligodendrogliomas and distinguish them from astrocytomas in IDH-mutated tumors. Although the consortium to inform molecular and practical approaches to CNS tumor taxonomy—not official WHO (cIMPACT-NOW) recommended a practical diagnostic scheme for diffuse gliomas based on the results of ATRX/p53 immunohistochemistry [16], the ATRX status is only a surrogate and sometimes inconclusive [24].

TERT promoter mutations are common in oligodendrogliomas and glioblastomas [4]. We and others have shown that *TERT* promoter mutations are frequently observed (>90%) in oligodendrogliomas with mutant *IDH* and 1p/19q codeletion, and that the presence of *TERT* promoter mutations is associated with favorable outcomes in IDH-mutated gliomas [6, 14, 15]. These findings strongly suggest that *TERT* promoter mutations may serve as an alternative diagnostic marker for oligodendrogliomas when combined with the *IDH* status. Another aspect of *TERT* promoter mutation is that this alteration without accompanying *IDH* mutation suggests clinically and biologically aggressive characteristics comparable with those of glioblastomas when found in histologically diagnosed as diffuse gliomas [6]. The presence of the *TERT* promoter mutation indicates the underestimation of the tumor grades when observed in grade II–III diffuse gliomas without *IDH* mutation. cIMPACT-NOW Update 3 recommended *TERT* promoter mutations as one of the three criteria (the other two being either *EGFR* amplification or combined whole chromosome 7 gain/chromosome 10 loss) to diagnosis “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma,

WHO grade IV” [8]. Thus, *TERT* promoter mutations serve as a diagnostic marker to delineate histologically verified IDH-wild diffuse astrocytomas with poor outcome comparable with glioblastomas. Evaluation of this marker is becoming an essential part of the routine diagnosis for diffuse astrocytic tumors with wildtype *IDH*. The bivalent impact of *TERT* promoter mutations on glioma biology depends on the *IDH* status, as such, we have previously proposed a molecular classification based on the *IDH* and *TERT* status, which can efficiently identify diffuse astrocytomas and oligodendrogliomas [6].

In this study, in order to further understand the diagnostic and prognostic value of *TERT* promoter mutation, we examined the impact of *TERT* promoter mutations on survival in a series of IDH-mutated glioma cases using a large retrospective tumor cohort. Our results showed that *TERT* promoter mutations predict favorable prognosis regardless of 1p/19q status in IDH-mutated gliomas. We propose that *TERT* promoter mutations are bivalent diagnostic and prognostic markers for adult diffuse gliomas.

Materials and methods

Patient cohorts

Two cohorts were integrated for this retrospective study: one that was analyzed in our previous study [6] and the other was newly collected for this study. The inclusion criteria for both cohorts were as follows: histological diagnosis of IDH1/2-mutated diffuse glioma, 18 years of age or older, clinical data obtained for survival analysis, and availability of genomic DNA extracted from frozen tissues at the time of initial surgery before chemoradiation. Out of the 951 cases analyzed in the previous study, 286 cases with *IDH* mutations from 13 institutions were enrolled in this study, and their clinical data were updated. The new cohort included 274 cases from 8 institutions. Thus, in total, 560 cases of IDH-mutated diffuse glioma were analyzed in the present study.

Clinical data and histology

Detailed clinical information including patient age, pre-operative Karnofsky Performance status (KPS) score, tumor location, extent of resection (EOR), and adjuvant therapy following the initial surgery was obtained from patient medical records. Local histological diagnosis made at each institution was obtained. The majority of tumors (540/560 cases, 96%) were operated on before

May 2016; thus, the histopathological diagnosis was almost entirely made according to the CNS WHO 2007 in each center. In this study, an integrated diagnosis was determined by incorporating molecular data and histological diagnosis, which made the diagnosis compatible with the CNS WHO 2016. WHO grade IV tumors with *IDH* mutation and 1p/19q codeletion were reclassified as grade III based on the current diagnostic criteria which classifies these as anaplastic oligodendrogliomas with *IDH* mutation and 1p/19q codeletion. The histological diagnosis of the original data is also provided in Additional file 1: Table S1 to show the relationship between molecular features and microscopic findings. For survival analysis, patients were subdivided into two groups based on age (≤ 50 or > 50 years) and preoperative KPS score (< 90 or $\geq 90\%$). These cutoffs were based on the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System, established and validated by a multi-institutional outcome analysis of cohorts consisting of low-grade gliomas [9, 10]. The EOR was based on the report made by the surgeons in the operation record of the initial surgery.

Molecular analysis

Genomic DNA from frozen tumor tissues was extracted using the DNeasy Blood & Tissue Kit (Qiagen, Tokyo, Japan), according to the manufacturer's protocol. Molecular testing was performed as previously described. Briefly, the mutational status of *IDH1/2* and *TERT* promoter was tested by Sanger sequencing and/or pyrosequencing [5, 6]. The 1p/19q status was examined by a multiplex ligation-dependent probe amplification (MLPA) [6], microsatellite analysis [23, 27], or microarray-based comparative genomic hybridization [1, 4]. The results of fluorescence in situ hybridization were not included to avoid ambiguity of judgment that could be caused by partial deletions in 1p and/or 19q [13]. The copy number of the *CDKN2A* locus was also determined by MLPA [6].

Statistical analysis

Categorized data were compared between molecular groups using a Chi square test. Survival was estimated by the Kaplan–Meier method and compared using a log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using the Cox regression model in patients with complete clinical information ($n = 557$). Overall survival (OS) was defined as the duration from the date of initial surgery to that of either death or the last follow-up, with a censoring cutoff date of 30 September 2017. Patients alive at the last follow-up were considered censored during the survival analysis. Differences were considered significant if the p value was < 0.05 . All

statistical analyses were performed using JMP Pro version 14 software (SAS Institute, Cary, NC, USA).

Results

Patient characteristics

A total of 560 diffuse glioma patients with confirmed *IDH* mutations were analyzed in the present study. The mean age of all patients was 43.5 years (range 18–82 years). Most patients were diagnosed with lower grade gliomas (527 cases, 94.1%) based on CNS WHO 2016. Approximately 82% (460 cases) of patients had only minor symptoms or no complaints (KPS score 90 or 100). The median follow-up period was 64.7 months (range; 0.85 to 208 months). *TERT* promoter mutation and 1p/19q codeletion were found in 303 (54.1%) and 285 (50.9%) cases, respectively. Among them, 279 cases harbored both *TERT* mutation and 1p/19q codeletion, while 30 cases had either *TERT* mutation ($n = 24$) or 1p/19q codeletion ($n = 6$). The remaining 251 *IDH*-mutant cases had neither of them. Infratentorial tumors with *IDH* mutation were extremely rare ($n = 3$) and harbored neither of *TERT* promoter mutation nor 1p/19q codeletion. The patients' clinical background and molecular status are summarized in Table 1, and detailed information for each case is provided in Additional file 1: Table S1.

TERT promoter mutation has a favorable impact on survival, independent of 1p/19q status

The results of a univariable Cox proportional hazard analysis for survival using each clinical and genetic factor are shown in Table 2. KPS score, WHO grade, *TERT* promoter status, 1p/19q status, adjuvant radiation therapy, and EOR were significantly associated with survival. The Kaplan–Meier survival curves also showed that both *TERT* promoter mutation and 1p/19q codeletion were strongly associated with a favorable prognosis in *IDH*-mutated gliomas (Additional file 2: Fig. S1A and B).

We further conducted a multivariable analysis using the Cox regression model for survival incorporating clinical factors and treatments (Table 2). *TERT* promoter mutation had a survival benefit with an HR of 0.421 (95% CI: 0.178–0.998, $p = 0.0494$), whereas the impact of 1p/19q status was not apparent (HR 0.648; 95% CI 0.262–1.604; $p = 0.349$). To elucidate the subgroup with a benefit or disadvantage from the *TERT* promoter mutation, we evaluated the HR of *TERT* promoter mutation by subgroup analysis in 1p/19q codeleted and intact groups, respectively. For this subgroup analysis, we performed multivariable analysis of the clinical factors that were considered to be significant in the initial multivariable analysis of all cases. The point estimates of HR consistently indicated the favorable impact of *TERT* promoter

Table 1 Patient characteristics (n = 560)

<i>IDH</i> <i>TERT</i> 1p/19q	All	mut mut codel	mut mut intact	mut wt codel	mut wt intact
Total (n)	560	279	24	6	251
Mean age (y.o.)	43.5	46.4	41.8	48.2	40.3
– 50	399	178	18	3	200
> 50	161	101	6	3	51
M/F	317/243	162/117	14/10	5/1	136/115
WHO grade ^a					
II	287	145	13	4	125
III	240	134	6	2	98
IV	33	0	5	0	28
Integrated diagnosis ^a					
DA	138	0	13	0	125
AA	104	0	6	0	98
OL	149	145	0	4	0
AO	136	134	0	2	0
GBM	33	0	5	0	28
KPS					
90–100	460	238	20	6	196
< 90	98	41	4	0	53
nd	2	0	0	0	2
Location					
Supratentorial	557	279	24	6	248
Infratentorial	3	0	0	0	3
<i>CDKN2A</i>					
Homo Del	19	3	1	1	14
Non-Del	365	187	17	3	158
nd	176	89	6	2	79
RT					
(+)	318	137	17	3	161
(–)	241	141	7	3	90
nd	1	1	0	0	0
Chemo					
(+)	379	210	16	3	150
(–)	180	68	8	3	101
nd	1	1	0	0	0
EOR					
90–100%	329	179	15	2	133
< 90%	231	100	9	4	118

AA, anaplastic astrocytoma, IDH-mutant; AO, anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted; Chemo, Chemotherapy; codel, codeleted; DA, diffuse astrocytoma, IDH-mutant; Del, Deletion; EOR, extent of resection; F, female; GBM, glioblastoma, IDH-mutant; Homo, Homozygous; nd, no data; KPS, Karnofsky Performance Status; M, male; mut, mutated; OL, oligodendroglioma, IDH-mutant and 1p/19q-codeleted; RT, radiation therapy; y.o., years old; wt, wild-type

^a Diagnosis based on CNS WHO2016

mutation regardless of the combination of clinical factors in both the 1p/19q codeleted and intact groups (Additional file 1: Table S2A–L and S3A–L).

The prognosis of the *IDH-TERT* co-mutated-1p/19q intact group was comparable to that of the *IDH-TERT* co-mutated-1p/19q codeleted group among WHO grade II–III cases

For the purpose of investigating the impact of *TERT* promoter mutation and 1p/19q codeletion on survival in IDH-mutated glioma cases, the patient cohort was divided into four groups dictated by *TERT* and 1p/19q statuses. The patient details of each group are shown in Table 1. The original histological diagnoses of the *TERT*-mutated-1p/19q intact (IDH-mutated) group included various histological types and contained fewer pure oligodendroglial tumors (9 out of 24 cases), while most *TERT*-wildtype-1p/19q codeleted tumors were histologically diagnosed as pure oligodendroglial tumors (5 out of 6 cases) (Additional file 1: Table S1).

The *TERT*-mutated-1p/19q intact group, including all histological grades, showed intermediate survival between that of the *TERT*-mutated-1p/19q codeleted and *TERT*-wildtype-1p/19q intact groups; however, the differences were not statistically significant ($p=0.17$ and 0.13 , respectively) (Fig. 1).

Further subgroup analysis was performed in the groups of grades II–III and IV because the Kaplan–Meier and Cox proportional hazard analyses demonstrated apparent differences between these grade groups (Additional file 2: Fig. S2 and Table 2). In the grade II–III glioma group, there was a significant difference in survival between the *TERT*-mutated-1p/19q codeleted group and *TERT*-wildtype-1p/19q intact group ($p<0.0001$) (Fig. 2a). The survival curve of the *TERT*-mutated-1p/19q intact group was close to that of the *TERT*-mutated-1p/19q codeleted group. The *TERT*-mutated-1p/19q intact group showed a tendency towards longer survival than that of the *TERT*-wildtype-1p/19q intact group, although the difference was not statistically significant ($p=0.11$); this is probably because of the limited number of these rare cases in the cohort (Fig. 2a). The survival curve of the *TERT*-wildtype-1p/19q codeleted group was close to that of the *TERT*-wildtype-1p/19q intact group (Fig. 2a). In the grade IV tumor group, the *TERT*-mutated-1p/19q intact group showed a tendency towards longer survival compared with that of the *TERT*-wildtype-1p/19q intact group, although the difference was not statistically significant ($p=0.19$) (Fig. 2b). Thus, *TERT* promoter mutations without 1p/19q codeletion seemed to have a favorable impact on survival.

The favorable prognosis associated with *TERT* promoter mutations independent of 1p/19q codeletion was seen in grade II–III IDH-mutated cases with higher KPS scores (≥ 90)

We further analyzed the effect of *TERT* promoter mutation in IDH-mutated grade II–III tumors with respect to

Table 2 Univariable and multivariable Cox regression analysis for survival (n = 557)

	n	Univariable			Multivariable		
		HR	95% C.I.	p value	HR	95% C.I.	p value
Sex							
M	315	0.832	0.592–1.169	0.289	1.076	0.759–1.527	0.680
F	242	Ref			Ref		
Age							
–50	397	Ref			Ref		
>50	160	1.361	0.945–1.960	0.098	1.555	1.051–2.300	0.027
KPS							
90–100	459	Ref			Ref		
<90	98	2.833	1.971–4.074	<0.0001	1.706	1.136–2.562	0.010
WHO grade ^a							
II	285	Ref			Ref		
III	239	1.167	0.808–1.687	0.410	1.198	0.778–1.845	0.413
IV	33	8.646	5.135–14.558	<0.0001	5.761	2.978–11.145	<0.0001
<i>TERT</i>							
wt	255	Ref			Ref		
mut	302	0.278	0.191–0.404	<0.0001	0.421	0.178–0.998	0.0494
1p/19q							
Non-codel	273	Ref			Ref		
Codel	284	0.286	0.195–0.419	<0.0001	0.648	0.262–1.604	0.349
RT							
(–)	240	Ref			Ref		
(+)	317	1.555	1.084–2.232	0.017	0.847	0.531–1.349	0.484
Chemo							
(–)	179	Ref			Ref		
(+)	378	1.252	0.857–1.829	0.246	1.299	0.769–2.196	0.329
EOR							
90–100%	326	0.487	0.346–0.685	<0.0001	0.513	0.359–0.735	0.0003
<90%	231	Ref			Ref		

Chemo, Chemotherapy; C.I., Coefficient interval; codel, codeleted; EOR, extent of resection; F, female; HR, hazard ratio; KPS, Karnofsky Performance Status; M, male; mut, mutant; Ref, Reference; RT, radiation therapy; wt, wild-type


^a Diagnosis based on CNS WHO2016

prognosis after stratification by KPS scores. KPS score was a significant prognostic factor among pretreatment parameters (sex, age, and KPS score) in the univariable and multivariable Cox proportional hazard analyses (Table 2). Moreover, when the grade II–III group was subdivided by KPS scores, cases with a good performance status (KPS score of 90–100) showed favorable prognosis compared to those with a KPS score under 90 ($p=0.0002$) (Additional file 2 Fig. S3). When comparing molecular subgroups, the *TERT*-mutated groups with patients with grade II–III tumors and higher KPS scores (90–100) showed longer survival regardless of 1p/19q status (Fig. 2c). The *TERT*-mutated-1p/19q intact group showed significantly longer survival than that of the group with neither *TERT* promoter mutation nor 1p/19q codeletion ($p=0.032$), and the survival

of the former was comparable with that of the *TERT*-mutated-1p/19q codeleted group (Fig. 2c). The survival curve of the cases with higher KPS scores in the *TERT*-wildtype-1p/19q codeleted group was close to that of the *TERT*-wildtype-1p/19q intact group (Fig. 2c). On the other hand, neither 1p/19q codeletion nor *TERT* promoter mutation was associated with a favorable prognosis in subgroups with a lower KPS score (<90) (Fig. 2d). Only two *TERT*-mutated-1p/19q intact cases were included in the analysis for low KPS score.

Histological grade was associated with survival in 1p/19q intact cases but not in 1p/19q codeleted cases

We investigated the difference in the prognostic impact of histological grade on survival between 1p/19q intact and codeleted cases. When subdivided by 1p/19q status,



histological grade was not associated with survival in the 1p/19q codeleted cases but was significantly associated with prognosis in the 1p/19q intact IDH-mutated cases (Additional file 2: Fig. S4 A and B).

***CDKN2A* homozygous deletion was associated with shorter survival and higher histological grade among IDH-mutated-1p/19q intact tumors**


We also analyzed the prognostic relevance of *CDKN2A* in IDH-mutated tumor cases. *CDKN2A* status was available for 385 patients. *CDKN2A* homozygous deletion was observed in all molecular groups; however, the majority of deletions were found in those with *TERT*-wildtype-1p/19q intact tumors (Table 1). This alteration was associated with a higher grade ($p < 0.0001$) and a lower KPS score ($p < 0.0001$) compared to those of cases without this alteration. Tumors with *CDKN2A* homozygous deletion and 1p/19q codeletion were rare (4 cases), and as such, their effect on prognosis could not be evaluated (Additional file 2: Fig. S5A). In 1p/19q intact tumors, cases with *CDKN2A* homozygous deletion (n = 15) showed significantly shorter survival than those without this copy number alteration (n = 175) ($p < 0.0001$) (Additional file 2 Fig. S5B). Most of the *CDKN2A* deleted tumors without 1p/19q codeletion showed a higher histological grade

(grade II, one case; grade III, five cases; and grade IV, nine cases). When confined to the cases for which *CDKN2A* status was available, an unfavorable prognosis for WHO grade IV cases was retained even after excluding cases with *CDKN2A* homozygous deletion (Additional file 2: Fig. S5C).

Discussion

In this study, we investigated the survival impact of *TERT* promoter mutations in a large cohort of 560 IDH-mutated glioma cases with detailed patient data. We confirmed that majority of the *TERT* promoter mutations coincided with 1p/19q codeletion in IDH-mutated gliomas. However, there were notable exceptions, that is, 24 IDH-mutated tumors had *TERT* promoter mutations but not 1p/19q codeletion, whereas six tumors had 1p/19q codeletion without *TERT* promoter mutations. Multivariable analysis incorporating clinical background revealed that the prognostic impact of *TERT* promoter mutations was independent from that of 1p/19q codeletion (Table 2). In the subgroup analyses of grade II-III cases, the *TERT*-mutated-1p/19q intact group showed a favorable prognosis comparable to that of the *TERT*-mutated-1p/19q codeleted group, while the survival curve of the *TERT*-wildtype-1p/19q codeleted group was consistent with that of the *TERT*-wildtype-1p/19q intact group (Fig. 2a and c). These results of the subgroup analyses support the findings of the multivariable analyses.

A favorable prognostic impact of *TERT* promoter mutation in lower grade gliomas with an *IDH* mutation has been reported in several studies [6, 12, 14, 15]. However, whether *TERT* promoter mutations have an impact on patient survival independent of 1p/19q codeletion has not been fully investigated. We addressed this point by performing a multivariable analysis, first incorporating clinical factors. Our study also analyzed the prognosis of tumors with the “atypical” genotype of co-mutation in *IDH* and *TERT* without 1p/19q codeletion. The result of a large-scale retrospective study by Eckel-Passow et al. [12] indicated that this group of tumors had good prognosis comparable to that of triple-positive tumors, i.e., those with concurrent *IDH* mutation, *TERT* mutation, and 1p/19q codeletion. On the other hand, a follow-up of this study reported that *TERT* promoter mutation was a prognostic factor in 1p/19q codeleted cases, while the impact of *TERT* promoter mutation was not significant in 1p/19q intact cases [19]. However, in these studies, *TERT* mRNA expression was used as a surrogate for *TERT* mutational status in a considerable number of cases and, therefore, were not conclusive in their evaluation of the value of *TERT* promoter mutation as an independent prognostic marker in IDH-mutated gliomas [12,



19]. Another study involving over 300 IDH-mutated glioma cases also reported that survival of patients with *IDH-TERT* co-mutated tumors and grade II-III histology did not differ according to 1p/19q status [15]. Our results showed that *TERT* promoter mutations in IDH-mutated gliomas predict favorable prognosis regardless of 1p/19q status, highlighting the significant role of *TERT* promoter mutations as a prognostic marker. Significantly longer overall survival was seen in the *TERT*-mutated, 1p/19q intact, and IDH-mutated cases than in the *TERT*-wildtype, 1p/19q intact, and IDH-mutated cases, among patients with a high KPS score (90-100) in our study. Considering that even 1p/19q codeletion was not a prognostic indicator among patients with a low KPS (< 90), it appears that the relevance of molecular prognostic markers depends on the patient's clinical factors. This needs to be considered in future studies investigating molecular markers.

Although the *TERT*-mutated, 1p/19q intact, and IDH-mutated cases showed comparable survival with that of the triple-positive cases, the histology of the former varied. Whether the definition of oligodendroglioma depends on the tumor's histology or biological behavior anticipated by genotype, which is reflected in patient survival, is a matter for future debate. The current definition of oligodendroglial tumors in the CNS WHO 2016 prefers the latter [17]. On the other hand, the WHO classification is rapidly shifting from conventional morphology-based diagnosis to molecularly driven disease definition. Recognizing the significant impact of *IDH* mutation on the biology of astrocytic gliomas, cIMPACT-NOW update 5 has recently recommended a terminology "astrocytoma, IDH-mutated, grade 4" for the IDH-mutated diffuse astrocytic gliomas with histological/molecular features of glioblastoma, histological diagnosis over-riden by molecular features [7]. A diagnosis should reflect the biology of the tumor, the natural course of disease, and/or response to therapy. The present study and other studies have reported that 1p/19q codeletion without accompanying *TERT* promoter mutations does not have prognostic benefit [19]. Of note, all cases with such genotype were histologically diagnosed as oligodendroglial tumors in our series. The combination of *TERT* promoter mutations and *IDH* mutations is a highly specific biomarker. Considering that very few single genetic alterations can sufficiently define a tumor type (even 1p/19q codeletion needs to be used in combination with *IDH* status), *TERT* promoter mutation may deserve recognition as a diagnostic marker as well.

The prognostic relevance of WHO grading in IDH-mutated gliomas is controversial, although it is associated with tumor aggressiveness in their wildtype counterparts

[7, 18, 22, 26]. Our results showed that the survival of patients with IDH-mutated 1p/19q codeleted gliomas did not differ between WHO grade II and III cases (Additional file 2: Fig. S4A). The prognostic significance of WHO grading in molecularly proved oligodendrogliomas remains controversial; our result is comparable to another study [22] but in contrast with others [19]. As a nature of retrospective study, the differences in treatment variations including chemotherapy and radiation between WHO grading may have an impact on patient outcome. Future studies on oligodendroglial cases with controlled treatment background is warranted to assess this issue [19]. On the other hand, our results showed that the survival of patients with IDH-mutated astrocytomas differed among grade II, III, and IV tumors (Additional file 2: Fig. S4B); this result is comparable to those of some previous studies [25] but contrasts with others [18, 20]. Currently, the diagnosis of WHO grade II and III is essentially based on the mitotic index determined by microscopic observation of diffuse astrocytomas, and this has remained the same in the CNS WHO 2016 classification. Attempts to molecularly define the aggressive type of diffuse astrocytomas have suggested several genetic markers such as *RBI* pathway alterations (e.g., *CDKN2A/B* homozygous deletion or *CDK4* amplification), *PIK3R1* mutation, *PDGFRA* amplification, or G-CIMP low type in the methylation cluster [2, 3, 7, 11, 21, 25]. Of these, the *CDKN2A* homozygous deletion has been proposed as a strong prognostic factor in IDH-mutated astrocytomas [3, 21, 25]. In our series, high histological grade and *CDKN2A* homozygous deletion were adverse prognostic factors in IDH-mutated-1p/19q intact gliomas. This is in line with previous reports [21]. However, the frequency of this copy number change was relatively low and strongly correlated with high histological grades. IDH-mutated glioblastomas without *CDKN2A* homozygous deletion still showed poorer prognosis compared with that of lower grade astrocytomas (Additional file 2: Fig. S5C). WHO grade IV was an independent risk factor for survival in the multivariable analysis for all cases (Table 2) and the subsequent subgroup analysis for 1p/19q intact tumors (Additional file 1: Table S3L). Thus, histologically defined grade IV tumors may have a fundamentally different biology from grade II-III tumors [7]. Further exploration of molecular markers indicating aggressive IDH-mutated astrocytomas is warranted. In the meantime, histologically defined WHO grading still appears to have an impact on the delineation of biologically and clinically malignant astrocytomas with *IDH* mutation.

Conclusions

Our results provide strong evidence that *TERT* promoter mutation confers a favorable prognosis regardless of the 1p/19q status in IDH-mutated gliomas. This observation was most evident in grade II–III gliomas as evidenced by subgroup analyses. *TERT* promoter mutations may not serve as diagnostic markers on their own as there are other types of IDH-wildtype glial neoplasms that may harbor *TERT* promoter mutations, including pleomorphic xanthoastrocytoma, ganglioglioma, anaplastic glioma with piloid features, and ependymoma [8]. However, very few molecular markers serve as standalone diagnostic markers for gliomas. Even *IDH* mutations or 1p/19q codeletion has to be used in combination to define a single entity of diffuse glioma [16, 20]. In line with this, it has been shown that *TERT* promoter mutations when combined with *IDH* mutation status serve as a very powerful prognostic predictor in diffuse gliomas. Given the current trend of using molecular and biological markers for diagnosis, it is worthwhile to consider *TERT* promoter mutation as a diagnostic as well as prognostic marker.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s40478-020-01078-2>.

Additional file 1: Table S1 Detailed information of patients registered in the present study. Table S2 Cox regression analysis for survival in 1p/19q codeleted cases (n=284). Table S3 Cox regression analysis for survival in 1p/19q intact cases (n=273).

Additional file 2: Fig. S1. OS of all cases (n=560) stratified by *TERT* (A) or 1p/19q (B) status. Both *TERT* promoter mutation (A) and 1p/19q codeletion (B) were strongly associated with favorable prognosis in IDH-mutated gliomas. *codeI*, codeleted; OS, overall survival; and 5yOS, 5-year-overall survival. **Fig. S2 Kaplan-Meier analysis for OS in IDH-mutated gliomas.** Overall survival (OS) of all cases (n=560) stratified by histological grade. **Fig. S3. Kaplan-Meier analysis for overall survival (OS) stratified by KPS score in histological grade II-III cases.** When the grade II-III cohort was subdivided by the KPS score, cases with a good performance status (with a KPS score of 90-100) showed a more favorable prognosis than those with a KPS score under 90. *codeI*, codeleted; KPS, Karnofsky Performance Status; OS, overall survival; and 5yOS, 5-year-overall survival. **Fig. S4. Kaplan-Meier analysis for OS stratified by histological grade.** A. OS of 1p/19q codeleted cases (n=285) stratified by histological grade. B. OS of cases without 1p/19q codeletion (n=275) stratified by histological grade. *codeI*, codeleted; OS, overall survival; and 5yOS, 5-year-overall survival. **Fig. S5. Kaplan-Meier analysis for overall survival stratified by *CDKN2A* status in IDH-mutated gliomas without -1p/19q codeletion (A) and those with codeletion tumors (B).** A. The prognostic impact of *CDKN2A* homozygous deletion (n=4) was not apparent in the group with 1p/19q codeletion, although the number of cases was very small. B. In 1p/19q intact tumors, cases with *CDKN2A* homozygous deletion (n=15) showed significantly shorter survival than those without this copy number alteration. C. In 1p/19q intact cases, WHO grade IV cases showed unfavorable prognosis even when analyzing cases without *CDKN2A* homozygous deletion. *codeI*, codeleted; KPS, Karnofsky Performance Status; OS, overall survival; and 5yOS, 5-year-overall survival.

Abbreviations

CI: Confidence interval; cIMPACT-NOW: Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-not official WHO; CNS WHO 2016: The revised 4th edition of the World Health Organization (WHO) classification of Tumours of the Central Nervous System; EOR: Extent of resection; KPS: Karnofsky performance status; HR: Hazard ratio; MLPA: Multiplex ligation-dependent probe amplification; OS: Overall survival.

Acknowledgements

The authors thank all clinicians who took care of the patients and made a great contribution to this study by providing specimens and clinical information.

Author's contribution

HA, AK, KI: Study design. YMa, KY, NH, MO, SY, TSas, STan, FH, TI, KS, MK, KM, YMi, KTam, STam, TN, TU, YO, JF, DS, YH, ESP, RH, YI, YMi, KTan, STak, RO, TSak, KKo, RS, KKu, TSh, MNo, HS, MS, TK, HS, MM, HK, MNa, YS, TT, MNa, RN, YK, YN: Data collection. HA, RM: Data analysis. HA, RM, AK, YN, KI: Interpretation. HA, RM, AK, KI: Manuscript writing. All authors read and approved the final manuscript.

Funding

This investigation was supported by JSPS KAKENHI 16K20006 (H.A.) and the Research award of the Osaka Cancer Society (H.A.).

Availability of data and materials

The anonymized datasets analyzed in the present study are provided in supplementary information.

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Institutional Review Board (IRB) of the National Cancer Center (No. 2013-042) and the corresponding local IRB of the participating centers.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflicts of interest in association with this paper.

Author details

¹ Division of Brain Tumor Translational Research, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. ² Department of Neurosurgery, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita-City, Osaka 565-0871, Japan. ³ Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. ⁴ Biostatistics Division, Center for Research Administration and Support, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. ⁵ Department of Pediatric Hematology and Oncology, Osaka City General Hospital, 2-13-22, Miyakojima-hondori, Miyakojima-ku, Osaka-City, Osaka 534-0021, Japan. ⁶ Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka-City, Fukuoka 812-8582, Japan. ⁷ Department of Neurosurgery, Faculty of Medicine, Hokkaido University, North 15 West 7, Kita-ku, Sapporo-City, Hokkaido 060-8638, Japan. ⁸ Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe-City, Hyogo 650-0017, Japan. ⁹ Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. ¹⁰ Department of Neurosurgery, Dokkyo Medical University, 880, Kitakobayashi, Mibu-City, Tochigi 321-0293, Japan. ¹¹ Division of Neurological Surgery, Chiba Cancer Center, 666-2 Nitonacho, Chuo-ku, Chiba-City, Chiba 260-8717, Japan. ¹² Department of Neurosurgery, Kyorin University Faculty of Medicine, 6-20-2, Shinkawa, Mitaka-City, Tokyo 181-8611, Japan. ¹³ Department of Neurosurgery, Tohoku University Graduate School of Medicine, 1-1 Seiryomachi, Aoba-ku, Sendai-City, Miyagi 980-8574, Japan. ¹⁴ Department of Neurosurgery, Faculty of Medicine, Yamagata University, 2-2, Iida-Nishi, Yamagata-City, Yamagata

990-9585, Japan. ¹⁵ Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka-City, Saitama 350-1298, Japan. ¹⁶ Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, 3-9, Fukuura, Kanazawa-ku, Yokohama-City, Kanagawa 236-0004, Japan. ¹⁷ Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. ¹⁸ Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, 13-1, Takara-machi, Kanazawa-City, Ishikawa 920-8641, Japan. ¹⁹ Department of Neurosurgery, Osaka City University Graduate School of Medicine, 1-5-7, Asahi-machi, Abeno-ku, Osaka-City, Osaka 545-8586, Japan. ²⁰ Department of Neurosurgery, National Hospital Organization Osaka National Hospital, 2-1-14 Hoenzaka, Chuo-ku, Osaka-City, Osaka 540-0006, Japan. ²¹ Department of Neurosurgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka-City, Osaka 541-8567, Japan. ²² Department of Neurological Surgery, Wakayama Medical University, 811-1, Kimiidera, Wakayama-City, Wakayama 641-0012, Japan. ²³ Department of Neurosurgery, Hyogo College of Medicine, 1-1 Mukogawa, Nishinomiya-City, Hyogo 663-8501, Japan. ²⁴ Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama-City, Okayama 700-8558, Japan. ²⁵ Department of Neurosurgery, Keio University School of Medicine, 35, Shinano-machi, Tokyo, Shinjuku-ku 160-8582, Japan. ²⁶ Department of Neurosurgery, Tokyo Metropolitan Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. ²⁷ Department of Biomedical Research and Innovation Research, Institute for Clinical Research, National Hospital Organization Osaka National Hospital, 2-1-14, Hoenzaka, Chuo-ku, Osaka-City, Osaka 540-0006, Japan. ²⁸ Department of Neurosurgery, Kansai Medical University, 3-1, Shinmachi 2 Chome, Hirakata-City, Osaka 573-1191, Japan. ²⁹ Department of Pathology and Laboratory Medicine, National Hospital Organization, Sendai Medical Center, 2-11-12, Miyagino, Miyagino-ku, Sendai-City, Miyagi 983-8520, Japan. ³⁰ Central Clinical Laboratory, Hachioji Medical Center, Tokyo Medical University, 1163, Tatemachi, Hachioji-City, Tokyo 193-0998, Japan. ³¹ Department of Laboratory Medicine and Pathology (Neuropathology), Tokyo Metropolitan Neurological Hospital, 2-6-1 Musashidai, Fuchu, Tokyo 183-0042, Japan.

Received: 3 October 2020 Accepted: 11 November 2020
Published online: 23 November 2020

References

- Aihara K, Mukasa A, Nagae G, Nomura M, Yamamoto S, Ueda H, Tatsuno K, Shibahara J, Takahashi M, Momose T et al (2017) Genetic and epigenetic stability of oligodendrogliomas at recurrence. *Acta Neuropathol Commun* 5:18. <https://doi.org/10.1186/s40478-017-0422-z>
- Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T, Motomura K, Ohka F, Shiina S, Yamamoto T et al (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. *Neuro Oncol* 20:66–77. <https://doi.org/10.1093/neuonc/nox132>
- Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idibaïh A, Kamoun A et al (2019) CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. *Neuro Oncol* 21:1519–1528. <https://doi.org/10.1093/neuonc/noz124>
- Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N et al (2013) Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. *Acta Neuropathol* 126:267–276. <https://doi.org/10.1007/s00401-013-1141-6>
- Arita H, Narita Y, Matsushita Y, Fukushima S, Yoshida A, Takami H, Miyakita Y, Ohno M, Shibui S, Ichimura K (2015) Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas. *Brain Tumor Pathol* 32:22–30. <https://doi.org/10.1007/s10014-014-0186-0>
- Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S et al (2016) A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. *Acta Neuropathol Commun* 4:79. <https://doi.org/10.1186/s40478-016-0351-2>
- Brat DJ, Aldape K, Colman H, Figarella-Branger D, Fuller GN, Giannini C, Holland EC, Jenkins RB, Kleinschmidt-DeMasters B, Komori T et al (2020) cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. *Acta Neuropathol* 139:603–608. <https://doi.org/10.1007/s00401-020-02127-9>
- Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters BK, Perry A, Reifenberger G, Stupp R et al (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. *Acta Neuropathol* 136:805–810. <https://doi.org/10.1007/s00401-018-1913-0>
- Chang EF, Clark A, Jensen RL, Bernstein M, Guha A, Carrabba G, Mukhopadhyay D, Kim W, Liao LM, Chang SM et al (2009) Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. *Clinical article. J Neurosurg* 111:203–210. <https://doi.org/10.3171/2009.2.JNS081101>
- Chang EF, Smith JS, Chang SM, Lamborn KR, Prados MD, Butowski N, Barbaro NM, Parsa AT, Berger MS, McDermott MM (2008) Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. *J Neurosurg* 109:817–824. <https://doi.org/10.3171/JNS/2008/109/11/0817>
- de Souza CF, Sabedot TS, Malta TM, Stetson L, Morozova O, Sokolov A, Laird PW, Wiznerowicz M, Iavarone A, Snyder J et al (2018) A distinct DNA methylation shift in a subset of glioma CpG island methylation phenotypes during tumor recurrence. *Cell Rep* 23:637–651. <https://doi.org/10.1016/j.celrep.2018.03.107>
- Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. *N Engl J Med* 372:2499–2508. <https://doi.org/10.1056/NEJMoa1407279>
- Ichimura K, Vogazianou AP, Liu L, Pearson DM, Backlund LM, Plant K, Baird K, Langford CF, Gregory SG, Collins VP (2008) 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. *Oncogene* 27:2097–2108. <https://doi.org/10.1038/sj.onc.1210848>
- Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK et al (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. *Oncotarget* 5:1515–1525. <https://doi.org/10.18632/oncotarget.1765>
- Labussiere M, Di Stefano AL, Gleize V, Boisselier B, Giry M, Mangesius S, Bruno A, Paterà R, Marie Y, Rahimian A et al (2014) TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. *Br J Cancer* 111:2024–2032. <https://doi.org/10.1038/bjc.2014.538>
- Louis DN, Giannini C, Capper D, Paulus W, Figarella-Branger D, Lopes MB, Batchelor TT, Cairncross JG, van den Bent M, Wick W et al (2018) cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. *Acta Neuropathol* 135:639–642. <https://doi.org/10.1007/s00401-018-1826-y>
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Reifenberger G, von Deimling A (2016) World Health Organization histological classification of tumours of the central nervous system. *International Agency for Research on Cancer, City*
- Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR, Armstrong TS, Sulman EP, Cahill DP, Vera-Bolanos E et al (2015) IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas. *Acta Neuropathol* 129:585–596. <https://doi.org/10.1007/s00401-015-1398-z>
- Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G et al (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. *Acta Neuropathol* 133:1001–1016. <https://doi.org/10.1007/s00401-017-1690-1>
- Reuss DE, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A, Sahm F, Koelsche C, Korshunov A, Olar A et al (2015) IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. *Acta Neuropathol* 129:867–873. <https://doi.org/10.1007/s00401-015-1438-8>
- Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F, Koelsche C, Wefers A, Reinhardt A, Huang K et al (2018) Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. *Acta Neuropathol* 136:153–166. <https://doi.org/10.1007/s00401-018-1849-4>

22. Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, Shimamura T, Niida A, Motomura K, Ohka F et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. *Nat Genet* 47:458–468. <https://doi.org/10.1038/ng.3273>
23. Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N, Fujimaki T, Hojo S, Kubo O, Ide T et al (2002) Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. *Clin Cancer Res* 8:196–201
24. Yamamichi A, Ohka F, Aoki K, Suzuki H, Kato A, Hirano M, Motomura K, Tanahashi K, Chalise L, Maeda S et al (2018) Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion. *Brain Tumor Pathol* 35:106–113. <https://doi.org/10.1007/s10014-018-0312-5>
25. Yang RR, Shi ZF, Zhang ZY, Chan AK, Aibaidula A, Wang WW, Kwan JSH, Poon WS, Chen H, Li WC et al (2019) IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. *Brain Pathol*. <https://doi.org/10.1111/bpa.12801>
26. Yoda RA, Marxen T, Longo L, Ene C, Wirsching HG, Keene CD, Holland EC, Cimino PJ (2019) Mitotic index thresholds do not predict clinical outcome for IDH-mutant astrocytoma. *J Neuropathol Exp Neurol* 78:1002–1010. <https://doi.org/10.1093/jnen/nlz082>
27. Yoshimoto K, Iwaki T, Inamura T, Fukui M, Tahira T, Hayashi K (2002) Multiplexed analysis of post-PCR fluorescence-labeled microsatellite alleles and statistical evaluation of their imbalance in brain tumors. *Jpn J Cancer Res* 93:284–290. <https://doi.org/10.1111/j.1349-7006.2002.tb02170.x>

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

